WO2011081294A3 - 항혈관신생 활성을 가지는 재조합 아데노바이러스 - Google Patents

항혈관신생 활성을 가지는 재조합 아데노바이러스 Download PDF

Info

Publication number
WO2011081294A3
WO2011081294A3 PCT/KR2010/007864 KR2010007864W WO2011081294A3 WO 2011081294 A3 WO2011081294 A3 WO 2011081294A3 KR 2010007864 W KR2010007864 W KR 2010007864W WO 2011081294 A3 WO2011081294 A3 WO 2011081294A3
Authority
WO
WIPO (PCT)
Prior art keywords
recombinant adenovirus
angiogenesis
present
adenovirus
vegfr
Prior art date
Application number
PCT/KR2010/007864
Other languages
English (en)
French (fr)
Other versions
WO2011081294A2 (ko
Inventor
윤채옥
Original Assignee
연세대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 산학협력단 filed Critical 연세대학교 산학협력단
Priority to CN2010800599056A priority Critical patent/CN102712934A/zh
Priority to JP2012546984A priority patent/JP2013516169A/ja
Priority to US13/519,934 priority patent/US20130101557A1/en
Publication of WO2011081294A2 publication Critical patent/WO2011081294A2/ko
Publication of WO2011081294A3 publication Critical patent/WO2011081294A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)

Abstract

본 발명은 (a) 아데노바이러스의 ITR (inverted terminal repeat) 뉴클레오타이드 서열; 및 (b) (i) VEGFR-1(Vascular Endothelial Growth Factor Receptor 1)의 세포외 도메인과 (ii) VEGFR-2(Vascular Endothelial Growth Factor Receptor 2)의 세포외 도메인을 포함하는 키메릭 데코이 수용체(chimeric decoy receptor)를 코딩하는 뉴클레오타이드 서열을 포함하는 혈관신생 억제능이 개선된 재조합 아데노바이러스 및 이를 포함하는 약제학적 혈관신생 억제용 조성물에 관한 것이다. 키메릭 데코이 수용체를 발현하는 본 발명의 재조합 아데노바이러스는 혈관신생을 매우 효과적으로 억제하여, 다양한 혈관신생-관련 질환의 유전자치료제로 이용될 수 있다. 특히, 본 발명의 재조합 아데노바이러스는 종양세포 살상능이 우수하다.
PCT/KR2010/007864 2009-12-31 2010-11-09 항혈관신생 활성을 가지는 재조합 아데노바이러스 WO2011081294A2 (ko)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN2010800599056A CN102712934A (zh) 2009-12-31 2010-11-09 具有抗血管新生活性的重组腺病毒
JP2012546984A JP2013516169A (ja) 2009-12-31 2010-11-09 抗血管新生活性を有する組換えアデノウイルス
US13/519,934 US20130101557A1 (en) 2009-12-31 2010-11-09 Recombinant Adenovirus Having Anti-Angiogenesis Activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090135629A KR101248912B1 (ko) 2009-12-31 2009-12-31 항혈관신생 활성을 가지는 재조합 아데노바이러스
KR10-2009-0135629 2009-12-31

Publications (2)

Publication Number Publication Date
WO2011081294A2 WO2011081294A2 (ko) 2011-07-07
WO2011081294A3 true WO2011081294A3 (ko) 2011-10-06

Family

ID=44226932

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/007864 WO2011081294A2 (ko) 2009-12-31 2010-11-09 항혈관신생 활성을 가지는 재조합 아데노바이러스

Country Status (5)

Country Link
US (1) US20130101557A1 (ko)
JP (1) JP2013516169A (ko)
KR (1) KR101248912B1 (ko)
CN (1) CN102712934A (ko)
WO (1) WO2011081294A2 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201502941VA (en) 2012-10-17 2015-05-28 Vascular Biogenics Ltd Treatment methods using adenovirus
WO2014153204A1 (en) 2013-03-14 2014-09-25 Salk Institute For Biological Studies Oncolytic adenovirus compositions
CN104419714A (zh) * 2013-08-26 2015-03-18 深圳先进技术研究院 抑制肿瘤血管新生的融合蛋白的基因及其构建方法和应用
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
WO2018111767A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
CN109576231B (zh) * 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
EP3743091A4 (en) * 2018-01-26 2021-12-15 The Regents of the University of California METHODS AND COMPOSITIONS FOR THE TREATMENT OF ANGIOGENIC DISORDERS USING ANTI-VEGF AGENTS
WO2021108255A1 (en) 2019-11-25 2021-06-03 The Regents Of The University Of California Long-acting vegf inhibitors for intraocular neovascularization

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100528727B1 (ko) * 2002-04-30 2005-11-15 윤채옥 종양 특이적이며 세포 고사를 유발하여 개선된 종양 살상효과를 나타내는 재조합 아데노바이러스 및 이를 포함하는약제학적 항종양 조성물
KR100746122B1 (ko) * 2004-05-10 2007-08-03 연세대학교 산학협력단 Ｒｂ-결합능이 상실된 개선된 종양세포-특이 세포살상능을 나타내는 재조합 아데노바이러스

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0928203B1 (en) * 1996-09-24 2006-10-25 Merck & Co., Inc. Compounds for the inhibition of angiogenesis by gene therapy
CN1397641A (zh) * 2001-05-25 2003-02-19 钱其军 表达血管生成抑制因子的肿瘤细胞内增殖的病毒及其构建方法
CN1339604A (zh) * 2001-09-13 2002-03-13 杨启成 带有腺相关病毒末端序列的基因载体及其应用
CN1542132A (zh) * 2003-04-30 2004-11-03 上海新霁生物科技有限公司 高效表达治疗肿瘤并含有人恒定区全抗体基因的重组病毒及其用途
KR20050088506A (ko) * 2004-03-02 2005-09-07 삼성전자주식회사 다중 세정도를 지원하는 확장형 몽고메리 모듈러 곱셈기
WO2006001888A2 (en) * 2004-04-16 2006-01-05 Acuity Pharmaceuticals Inc Compositions and methods for inhibiting angiogenesis
CN1304427C (zh) * 2004-06-08 2007-03-14 成都康弘生物科技有限公司 抑制血管新生的融合蛋白质及其用途
EP1767546B1 (en) * 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Angiogenesis-inhibiting chimeric protein and the use
KR100563099B1 (ko) * 2005-07-26 2006-03-27 충청북도 ＶＥＧＦＲ 트렁케이티드 솔루블 ｃＤＮＡ를 함유하는재조합 아데노-연관 바이러스（ｒＡＡＶ）및 이를 함유하는대장암, 방광암 및/또는 폐암 특이적 유전자 치료제
US8216575B2 (en) * 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
CN100582232C (zh) * 2006-06-22 2010-01-20 江苏舜唐生物工程有限公司 一种具有多重特异性抗癌机制的溶瘤腺病毒突变体
CN101279092B (zh) * 2007-04-02 2010-10-27 成都康弘生物科技有限公司 Vegf受体融合蛋白在制备治疗与血管生成有关的疾病中的应用
KR100911624B1 (ko) * 2007-05-14 2009-08-12 연세대학교 산학협력단 Ｉｌ－１２ 및 ｉｌ－２３의 효율적인 공동발현 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100528727B1 (ko) * 2002-04-30 2005-11-15 윤채옥 종양 특이적이며 세포 고사를 유발하여 개선된 종양 살상효과를 나타내는 재조합 아데노바이러스 및 이를 포함하는약제학적 항종양 조성물
KR100746122B1 (ko) * 2004-05-10 2007-08-03 연세대학교 산학협력단 Ｒｂ-결합능이 상실된 개선된 종양세포-특이 세포살상능을 나타내는 재조합 아데노바이러스

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOLASH, J. ET AL.: "VEGF-Trap: a VEGF blocker with potent antitumor effects", PROC. NATL. ACAD. SCI. USA., vol. 99, no. 17, 20 August 2002 (2002-08-20), pages 11393 - 11398, XP002611390, DOI: doi:10.1073/pnas.172398299 *
HUTTER, R. ET AL.: "Vascular endothelial growth factor regulates reendothelialization and neointima formation in a mouse model of arterial injury", CIRCULATION, vol. 110, no. 16, 19 October 2004 (2004-10-19), pages 2430 - 2435, XP003029982, DOI: doi:10.1161/01.CIR.0000145120.37891.8A *

Also Published As

Publication number Publication date
WO2011081294A2 (ko) 2011-07-07
KR20110078744A (ko) 2011-07-07
CN102712934A (zh) 2012-10-03
KR101248912B1 (ko) 2013-03-29
US20130101557A1 (en) 2013-04-25
JP2013516169A (ja) 2013-05-13

Similar Documents

Publication Publication Date Title
WO2011081294A3 (ko) 항혈관신생 활성을 가지는 재조합 아데노바이러스
MX2020001912A (es) Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso.
PH12019500694A1 (en) Factor viii compositions and methods of making and using the same
MX340515B (es) Terapia antidiabética vasoprotectora y cardioprotectora.
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
MX354555B (es) Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso.
JP2012529436A5 (ko)
JP2015134796A5 (ko)
MX359953B (es) Ácido nucleico que comprende o que codifica un tallo-rizo de histona y una secuencia poli (a) o una señal de poliadenilación para incrementar la expresión de una proteína terapéutica codificada.
WO2011084808A3 (en) Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
NZ603348A (en) Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
NZ584827A (en) Antisense modulation of fibroblast growth factor receptor 4 expression
MY188182A (en) Acylated glucagon analogues
NZ628385A (en) Batches of recombinant adenovirus with altered terminal ends
MX2022013520A (es) Polipeptidos que se enlazan a cxcr2.
SG10201406288SA (en) Multimeric forms of antimicrobial peptides
WO2012077950A3 (ko) 히알루론산-단백질 컨쥬게이트 및 이의 제조 방법
ZA202202410B (en) Rna particles comprising polysarcosine
MX2012001306A (es) Inhibicion de matastasis de tumor.
WO2012057575A3 (ko) 울금 추출물 및 스테비아 추출물을 유효성분으로 포함하는 흰점 증후군 바이러스에 대한 내성 증강용 사료 첨가제 조성물 및 이를 포함하는 사료 조성물
AP3277A (en) Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases
EP4306123A3 (en) Saposin-a derived peptides and uses thereof
IN2014DN06920A (ko)
NZ609440A (en) Preventative or therapeutic agent for fibrosis
WO2007112001A3 (en) Compositions and methods for treating myocardial infarction

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080059905.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10841127

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2012546984

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13519934

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 10841127

Country of ref document: EP

Kind code of ref document: A2